Indication
Indicated to reduce the risk of myocardial infarction (MI), stroke, coronary revascularization, and cardiovascular death in patients with atherosclerotic disease or with multiple risk factors for cardiovascular disease.
Loading your page…
Loading your page…
Myocardial Infarction;Stroke;Coronary Artery Disease
Marketing Authorisation Holder: Agepha Pharma s.r.o.
INN: colchicine
AI Drug & Interaction Analysis
Free account required
Ask Osler about Colchicine Agepha Pharma: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.